Olfactory dysfunction represents a significant but often underappreciated feature of progressive supranuclear palsy (PSP). While traditionally associated with Parkinson's disease (PD), where it serves as a well-established prodromal marker, olfactory impairment in PSP provides valuable insights into disease pathology, aids in differential diagnosis, and may contribute to understanding the spread of tau pathology through olfactory pathways.
¶ Prevalence and Clinical Features
Olfactory dysfunction in PSP is common but differs in pattern from PD:
| Measure |
PSP |
Parkinson's Disease |
CBS |
| Olfactory dysfunction prevalence |
50-70% |
90-95% |
40-60% |
| Severe impairment (anosmia) |
15-25% |
50-70% |
10-20% |
| Mild-moderate impairment |
35-45% |
20-30% |
30-40% |
| Early-stage detection rate |
30-40% |
70-80% |
20-30% |
The olfactory profile in PSP exhibits several distinctive features:
- Pattern of Loss: Mixed olfactory dysfunction affecting both identification and detection thresholds, with relatively preserved odor discrimination compared to PD
- Temporal Profile: Often present at diagnosis, may precede motor symptoms in some cases
- Progression: Generally stable or slowly progressive, less dramatic decline than PD
- Symmetry: No significant lateralization differences
The olfactory dysfunction in PSP stems from tau pathology affecting multiple components of the olfactory system:
- Olfactory bulb: Variable involvement with neurofibrillary tangles in mitral and tufted cells
- Anterior olfactory nucleus: Tau-positive neurons with reduced counts
- Olfactory tract: Degeneration of myelinated fibers
- Orbitofrontal cortex: Primary olfactory cortex involvement
- Piriform cortex: Essential for odor discrimination
- Anterior commissure: Transcallosal olfactory connections
- Amygdala: Emotional processing of odors
Autopsy studies reveal tau pathology in olfactory regions:
- Olfactory bulb: Neurofibrillary tangles in 40-60% of PSP cases
- Anterior olfactory nucleus: Nearly universal involvement
- Piriform cortex: Moderate to severe pathology in most cases
- Entorhinal cortex: Early and severe involvement (Braak staging)
Olfactory dysfunction varies across PSP phenotypes:
- Richardson syndrome (PSP-RS): Most consistent olfactory impairment (50-70%)
- PSP-Parkinsonism (PSP-P): Similar rates to PSP-RS
- PSP-Pure Akinesia with Gait Freezing (PSP-PAGF): Often preserved olfaction
- Corticobasal syndrome (CBS): Variable, depending on tau burden
The olfactory bulb represents the primary relay station for odor information, and its involvement in PSP provides critical insights into disease progression:
The olfactory bulb in PSP demonstrates characteristic tau pathology affecting multiple neuronal populations:
- Mitral cells: Primary projection neurons showing neurofibrillary tangles (NFTs) in approximately 40-60% of cases
- Tufted cells: Secondary projection neurons with comparable tau burden
- Granule cells: Interneurons with lesser but significant involvement
- Periglomerular cells: Early involvement in some cases
Beyond neuronal involvement, glial cells contribute to olfactory bulb dysfunction:
- Oligodendrocytes: Tau-positive coiled bodies along myelinated fibers
- Astrocytes: Tau pathology in astrocytic processes
- Microglia: Activated microglia associated with tau deposits
¶ Braak Staging and Olfactory Bulb
The progression of tau pathology in PSP follows patterns described by Braak staging, with the olfactory bulb representing an early stage:
| Stage |
Olfactory Bulb Involvement |
Clinical Correlation |
| Stage 0-1 |
No involvement |
Presymptomatic |
| Stage 2 |
Mild involvement, anterior olfactory nucleus |
Mild olfactory changes |
| Stage 3 |
Moderate involvement, mitral cells affected |
Overt olfactory dysfunction |
| Stage 4-5 |
Severe involvement, global atrophy |
Significant impairment |
| Stage 6 |
Near-complete degeneration |
Severe anosmia |
Olfactory bulb pathology produces measurable functional deficits:
- Reduced olfactory discrimination: Inability to distinguish between similar odors
- Elevated detection thresholds: Requires higher odor concentrations for perception
- Impaired odor memory: Difficulty associating smells with past experiences
- Altered odor perception: Parosmia (distorted smell perception) in some cases
Structural and functional imaging reveals olfactory bulb changes:
- Volumetric MRI: Reduced olfactory bulb volume in PSP vs. controls
- Diffusion tensor imaging: Increased mean diffusivity in olfactory tracts
- PET metabolism: Hypometabolism in primary olfactory cortex
Both PSP and PD demonstrate olfactory dysfunction, but important distinctions exist:
| Feature |
PSP |
Parkinson's Disease |
| Prevalence |
50-70% |
90-95% |
| Severity |
Mild-moderate |
Severe |
| Age of onset |
Similar |
Similar |
| Disease duration effect |
Less pronounced |
More pronounced |
| Sex distribution |
Equal |
Slight male predominance |
The underlying mechanisms differ substantially between these conditions:
- Primary pathology: 4R-tau aggregation in neurons and glia
- Propagation pattern: Retrograde degeneration from brainstem
- Olfactory structures affected: Primary and secondary olfactory regions
- Neurotransmitter involvement: Multiple including GABA and glutamate
- Primary pathology: Alpha-synuclein (α-syn) aggregation in neurons
- Propagation pattern: Braak staging - spreads from olfactory bulb and enteric nervous system
- Olfactory structures affected: Primarily olfactory bulb and anterior olfactory nucleus
- Neurotransmitter involvement: Dopaminergic and cholinergic deficits
The olfactory dysfunction profile differs between PSP and PD:
- PD: Markedly elevated thresholds, especially for pleasant odors
- PSP: Moderately elevated thresholds, less selective
- PD: Severely impaired identification ability
- PSP: Moderately impaired, with better preservation
- PD: Severely impaired odor discrimination
- PSP: Relatively preserved discrimination abilities
- PD: Progressive decline with disease duration
- PSP: More stable, less progressive impairment
The timing of olfactory dysfunction relative to motor symptoms differs:
- PD: Often predates motor symptoms by 5-10 years
- PSP: Variable timing, less reliable prodromal marker
- Combined utility: Olfactory testing helps differentiate when combined with other markers
The 4-repeat tau isoform (4R-tau) characteristic of PSP demonstrates unique aggregation patterns in olfactory regions:
- Hyperphosphorylation: Multiple kinases contribute to tau phosphorylation in olfactory neurons
- Oligomer formation: Soluble tau oligomers precede insoluble aggregate formation
- Fibril propagation: Tau fibrils spread transneuronally through olfactory pathways
- Cellular toxicity: Both loss-of-function and gain-of-toxic-function mechanisms
- GSK-3β: Constitutively active in olfactory bulb neurons
- CDK5: Activity regulated by p35/p39
- MAPK family: ERK1/2 activation in tau phosphorylation
Different olfactory regions show varying susceptibility to tau pathology:
- Anterior olfactory nucleus: Nearly 100% involvement in PSP
- Piriform cortex: 80-90% involvement
- Entorhinal cortex: 70-80% involvement (critical memory interface)
- Olfactory tubercle: 50-60% involvement
- Orbitofrontal cortex: 40-50% involvement
- Amygdala: 30-40% involvement
- Primary olfactory cortex: Variable involvement
- Olfactory bulb: 40-60% involvement
The spread of tau pathology through olfactory pathways follows multiple potential mechanisms:
- Synaptic connections: Tau travels along established neural circuits
- Olfactory tract: Direct pathway from bulb to cortex
- Lateral olfactory tract: Connections to amygdala and hypothalamus
- Tau secretion: Neuronal release of tau species
- Exosomal transport: Tau within extracellular vesicles
- Direct extracellular spread: Tau peptides in interstitial space
The distribution of olfactory tau pathology correlates with clinical presentations:
- Widespread olfactory region involvement
- Correlation with UPSIT scores
- Predicts rapid disease progression
- Similar but less severe involvement
- Greater asymmetry in some cases
- Relative preservation of olfactory regions
- Explains preserved olfactory function
Understanding olfactory tau pathology informs therapeutic strategies:
- Intranasal delivery: Direct access to olfactory regions
- Olfactory bulb targeting: Potential for early intervention
- Anti-tau therapies: May benefit olfactory function
- CSF tau levels: Correlate with olfactory burden
- Olfactory testing: Non-invasive biomarker readouts
- Imaging markers: Tau PET in olfactory regions
Olfactory testing assists in differentiating PSP from other parkinsonian syndromes:
| Condition |
Typical Olfactory Function |
Utility |
| Parkinson's disease |
Severely impaired |
High |
| PSP |
Moderately impaired |
Moderate |
| CBS |
Variable |
Moderate |
| MSA |
Typically preserved |
High |
| CBD |
Variable |
Low-moderate |
A proposed olfactory scoring system for atypical parkinsonism:
- Normal olfaction → More likely MSA
- Mild-moderate impairment → Compatible with PSP or CBS
- Severe impairment → Suggests PD, unlikely PSP
Integrating olfactory testing with clinical assessment enhances diagnostic accuracy:
- Administer UPSIT or Sniffin' Sticks test
- Calculate composite score (TDI)
- Categorize: normosmia, mild, moderate, severe dysfunction
| Pattern |
Likely Diagnosis |
Confidence |
| Severe impairment (TDI < 16) |
PD |
High |
| Moderate impairment (TDI 16-25) |
PSP or CBS |
Moderate |
| Mild impairment (TDI 25-30) |
Early PSP/CBS |
Low |
| Normal olfaction (TDI > 30) |
MSA |
High |
Combine olfactory findings with:
- Motor examination: Vertical gaze palsy → increases PSP probability
- Autonomic testing: Orthostatic hypotension → increases MSA probability
- Cognitive profile: Frontal/executive dysfunction → increases PSP probability
- MRI findings: Midbrain atrophy → increases PSP probability
| UPSIT Score |
Interpretation |
Sensitivity for PSP |
Specificity vs. PD |
| ≥35 |
Normal |
- |
- |
| 30-34 |
Mild dysfunction |
65% |
70% |
| 25-29 |
Moderate dysfunction |
75% |
55% |
| <25 |
Severe dysfunction |
40% |
90% |
Olfactory testing provides valuable discriminatory power for differential diagnosis:
The most important distinction in clinical practice:
- Severe olfactory loss strongly favors PD over PSP
- Moderate impairment with vertical gaze palsy favors PSP
- Combined with other markers improves accuracy to >85%
Key distinguishing feature:
- Preserved olfaction strongly favors MSA (sensitivity 75-85%)
- Impaired olfaction in PSP helps exclude MSA
- Different pathological basis: MSA involves less olfactory tau
Overlapping but distinguishable:
- CBS with PSP pathology: Similar olfactory profile to PSP
- CBS with AD pathology: More severe impairment
- Asymmetric onset may predict CBS over PSP
Olfactory testing offers several practical advantages:
- Non-invasive: Simple psychophysical testing
- Cost-effective: Minimal equipment required
- Time-efficient: 10-15 minutes for comprehensive testing
- Objective: Quantifiable scores for monitoring
Olfactory measures function as part of a comprehensive biomarker panel:
| Biomarker Category |
PSP Signature |
Clinical Utility |
| Olfactory |
Moderate dysfunction |
Moderate |
| Neuroimaging |
Midbrain atrophy |
High |
| CSF biomarkers |
Elevated 4R-tau |
Moderate |
| Clinical markers |
Vertical gaze palsy |
High |
| Genetic |
MAPT mutations |
Moderate |
While less robust than in PD, olfactory testing may identify early PSP:
- Sensitivity in prodromal PSP: 30-40%
- Specificity: 70-80% compared to healthy controls
- Combined with other markers: Improves predictive value
- University of Pennsylvania Smell Identification Test (UPSIT): 40-item scratch-and-sniff test
- Sniffin' Sticks Test: 16-item screening test
- Threshold-Discrimination-Identification (TDI): Comprehensive assessment
- Olfactory event-related potentials (OERP): Late-latency responses
- Electro-olfactogram (EOG): Peripheral receptor activity
- MRI: Volumetric analysis of olfactory structures
- PET: Metabolic changes in piriform cortex
| TDI Score |
Interpretation |
PSP Probability |
| >30 |
Normosmia |
Low |
| 25-30 |
Mild dysfunction |
Low-moderate |
| 16-25 |
Moderate dysfunction |
Moderate |
| <16 |
Severe dysfunction |
Low (suggests PD) |
While both conditions involve olfactory dysfunction, key differences exist:
- Severity: PD typically shows more severe impairment
- Pattern: PD shows greater impairment in identification vs. detection
- Progression: More rapid decline in PD
- Pathology: Different underlying mechanisms (synuclein vs. tau)
The distinction is particularly relevant:
- MSA: Generally preserved olfaction
- PSP: Moderate impairment in majority
- Sensitivity: 75-85% for MSA vs. PSP differentiation
Overlap exists but differences emerge:
- CBS with PSP pathology: Similar to PSP
- CBS with AD pathology: More severe impairment
- Asymmetric presentations: May affect olfactory laterality
Olfactory dysfunction affects multiple domains:
- Food enjoyment: Reduced appetite and nutrition
- Safety: Inability to detect smoke, gas leaks
- Social interaction: Reduced quality of life
- Mood: Association with depression
- Visual cues for food identification
- Safety systems for hazard detection
- Enhanced food presentation (color, texture)
- Smoke detectors in all rooms
- Natural gas detectors
- Regular food expiration checks
- Enhanced flavoring of foods
- Texture-modified diets when needed
- Weight monitoring
Olfactory measures are being investigated as potential biomarkers:
- Disease progression: Correlation with clinical decline
- Therapeutic trials: Outcome measures
- Pathological correlation: Tau burden relationship
flowchart TD
A["Olfactory Epithelium"] -->|"Alpha-synuclein"| B["Olfactory Bulb"]
B --> C["Anterior Olfactory Nucleus"]
C --> D["Piriform Cortex"]
D --> E["Entorhinal Cortex"]
D --> F["Orbitofrontal Cortex"]
B -->|"Tau pathology"| G["Neurofibrillary Tangles"]
C -->|"Tau pathology"| G
D -->|"Tau pathology"| G
G --> H["Olfactory Dysfunction"]
G --> I["Memory Impairment"]
style G fill:#fff3e0,stroke:#333
style H fill:#9f9,stroke:#333
Advances in MRI technology enable detailed visualization of olfactory structures:
- 3D T1-weighted imaging: Volumetric analysis of olfactory bulb
- T2-weighted sequences: Detection of olfactory tract pathology
- Diffusion weighted imaging: Microstructural integrity assessment
- Quantitative metrics: Thickness, volume, signal intensity
¶ PET Ligand Development
Emerging tau PET ligands offer insights into olfactory region involvement:
- 18F-AV-1451 (Flortaucipir): Binds to tau tangles in olfactory regions
- 11C-PBB3: Multiple tau isoform binding
- Regional quantification: Olfactory bulb, piriform cortex, entorhinal cortex
Integration of multiple imaging modalities enhances diagnostic accuracy:
| Modality |
Information Gained |
PSP-Specific Findings |
| MRI volumetry |
Structural atrophy |
Reduced olfactory bulb volume |
| DTI |
White matter integrity |
Increased FA in olfactory tract |
| PET metabolism |
Functional activity |
Hypometabolism in piriform cortex |
| PET tau |
Tau deposition |
Tau binding in olfactory regions |
- High-resolution MRI: Olfactory bulb volumetry
- Diffusion tensor imaging: Olfactory tract integrity
- PET ligands: Tau deposition in olfactory regions
Ongoing research examines:
- Prodromal identification: Olfactory changes pre-diagnosis
- Progression markers: Predictive value over time
- Treatment response: Olfactory outcomes in trials